NASDAQ:RPID - Nasdaq - US75340L1044 - Common Stock - Currency: USD
3.15
-0.01 (-0.32%)
The current stock price of RPID is 3.15 USD. In the past month the price increased by 35.78%. In the past year, price increased by 284.15%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
TMO | THERMO FISHER SCIENTIFIC INC | 18.29 | 151.18B | ||
DHR | DANAHER CORP | 25.17 | 134.17B | ||
A | AGILENT TECHNOLOGIES INC | 20.66 | 31.27B | ||
IQV | IQVIA HOLDINGS INC | 12.22 | 24.34B | ||
MTD | METTLER-TOLEDO INTERNATIONAL | 28.08 | 23.67B | ||
WAT | WATERS CORP | 29.26 | 20.73B | ||
WST | WEST PHARMACEUTICAL SERVICES | 31.4 | 14.98B | ||
ILMN | ILLUMINA INC | 24.19 | 12.75B | ||
RVTY | REVVITY INC | 18.35 | 10.87B | ||
ICLR | ICON PLC | 9.26 | 10.48B | ||
TEM | TEMPUS AI INC | N/A | 10.25B | ||
QGEN | QIAGEN N.V. | 18.4 | 9.15B |
Rapid Micro Biosystems, Inc. is a life sciences technology company. The company is headquartered in Lexington, Massachusetts and currently employs 163 full-time employees. The company went IPO on 2021-07-15. Its flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in pharmaceutical manufacturing operations. The company offers four specific applications for testing of microbial contamination: Environmental Monitoring, which tests the manufacturing environment, including circulating air, exposed surfaces, and personnel; Water, which tests any purified water used at any stage of the drug production process, including water for injection; In-Process Bioburden, which tests raw materials, drug substance and in-process product, and Sterility Release offering final testing of finished product to ensure sterility before the product is released for commercial sale.
RAPID MICRO BIOSYSTEMS INC-A
25 Hartwell Avenue
Lexington MASSACHUSETTS US
CEO: Robert Spignesi
Employees: 193
Phone: 19783493200
The current stock price of RPID is 3.15 USD. The price decreased by -0.32% in the last trading session.
The exchange symbol of RAPID MICRO BIOSYSTEMS INC-A is RPID and it is listed on the Nasdaq exchange.
RPID stock is listed on the Nasdaq exchange.
9 analysts have analysed RPID and the average price target is 8.16 USD. This implies a price increase of 159.05% is expected in the next year compared to the current price of 3.15. Check the RAPID MICRO BIOSYSTEMS INC-A stock analysts ratings, price target forecast and up-and down grades for more detailed information.
RAPID MICRO BIOSYSTEMS INC-A (RPID) has a market capitalization of 138.06M USD. This makes RPID a Micro Cap stock.
RAPID MICRO BIOSYSTEMS INC-A (RPID) currently has 193 employees.
RAPID MICRO BIOSYSTEMS INC-A (RPID) has a support level at 3.14 and a resistance level at 3.28. Check the full technical report for a detailed analysis of RPID support and resistance levels.
The Revenue of RAPID MICRO BIOSYSTEMS INC-A (RPID) is expected to grow by 17.83% in the next year. Check the estimates tab for more information on the RPID EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
RPID does not pay a dividend.
RAPID MICRO BIOSYSTEMS INC-A (RPID) will report earnings on 2025-07-31, before the market open.
RAPID MICRO BIOSYSTEMS INC-A (RPID) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.03).
The outstanding short interest for RAPID MICRO BIOSYSTEMS INC-A (RPID) is 4.07% of its float. Check the ownership tab for more information on the RPID short interest.
ChartMill assigns a technical rating of 10 / 10 to RPID. When comparing the yearly performance of all stocks, RPID is one of the better performing stocks in the market, outperforming 98.87% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to RPID. RPID scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months RPID reported a non-GAAP Earnings per Share(EPS) of -1.03. The EPS increased by 14.88% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -47.76% | ||
ROE | -62.23% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 84% to RPID. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of 6.97% and a revenue growth 17.83% for RPID